Global initiative for glycolipid metabolic health
Peer-Reviewed Publication
Updates every hour. Last Updated: 6-Dec-2025 08:11 ET (6-Dec-2025 13:11 GMT/UTC)
Glycolipid metabolic disorders, linked to cardiovascular diseases and cancer, are a major global health challenge. Current single-disease treatments remain unsatisfied in reducing long-term risks. In 2024, Professor Jiao Guo along with global experts launched the "Global Initiative for Glycolipid Metabolic Health" to enhance prevention through scientific research, public education, and integrated management systems.
The DNA inside our cells is constantly being damaged, and one of the worst kinds of damage is a double-strand break—when both sides of the DNA helix are cut at once. Healthy cells can normally fix these breaks using highly precise repair systems, but when those systems fail, cells sometimes resort to a less accurate backup method. Now, scientists at Scripps Research have discovered when and how this backup repair pathway gets activated, and how the process could be turned against cancer cells that rely on it to survive.
New research by experts at the University of Sydney shows that breast density notification is leaving some women confused and anxious about their breast health. Breast density notification is being rolled out across Australia, but evidence suggests that women do not feel more informed by it. Between 25 and 40 percent of women have denser breast tissue which can make it harder for cancers to be detected through a mammogram.
A machine learning-based resource developed at St. Jude Children’s Research Hospital predicts which intrinsically disordered regions can drive the formation of biomolecular condensates and links those proteins to RNA biology.
Researchers identified that RASH3D19 creates a positive feedback loop that drives hyperactivity of RAS signaling and leads to tumor growth and treatment resistance
Reducing RASH3D19 also reduced tumor growth and sensitized cancer cells to KRAS inhibitors
Combining RASH3D19 blockers with KRAS inhibitors improved outcomes in preclinical models